Why the study?
Does adjunctive therapy with beta blockers, nitrates, ACE inhibitors, or magnesium provide incremental benefit in patients with acute myocardial infarction receiving thrombolytic therapy?
Does adjunctive therapy with beta blockers, nitrates, ACE inhibitors, or magnesium provide incremental benefit in patients with acute myocardial infarction receiving thrombolytic therapy?
This review explores the incremental benefit of adjunctive pharmacologic therapies like beta blockers, nitrates, ACE inhibitors, and magnesium in the era of thrombolytic therapy for acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Adjunctive therapies with thrombolysis in AMI remain uncertain; leaves open their incremental value amid modern reperfusion.
The current era has witnessed dramatic improvement in the treatment of acute myocardial infarction, due in large part to the more widespread use of thrombolytic therapy aimed at quickly restoring perfusion in the infarct-related artery. This review addresses the role of adjunctive pharmacologic therapy in the thrombolytic era, recognizing that much of the available clinical trial data supporting the role of adjunctive pharmacologic treatment strategies was conducted in patient populations not widely exposed to reperfusion therapy. This review, therefore, explores the data supporting the incremental benefit of therapy with beta blockers, nitrates, angiotensin-converting enzyme inhibitors, or magnesium in addition to thrombolytic therapy. Heparin and aspirin will not be discussed.
No takes yet. Share an insight, caveat, or question.
Dries et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: